



## Johnson & Johnson Reports 2009 First-Quarter Results:

### --Sales of \$15.0 Billion Decreased 7.2% Versus 2008 First Quarter; --EPS was \$1.26, Equal to a Year Ago

NEW BRUNSWICK, N.J., April 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of \$15.0 billion for the first quarter of 2009, a decrease of 7.2% as compared to the first quarter of 2008. Operational results declined 1.2% and the negative impact of currency was 6.0%. Domestic sales declined 5.0%, while international sales declined 9.6%, reflecting operational growth of 3.0% and a negative currency impact of 12.6%.

Net earnings for the first quarter of 2009 were \$3.5 billion, representing a decrease of 2.5%, as compared to the same period in 2008. Diluted earnings per share for the first quarter of 2009 was \$1.26, the same versus a year ago. The Company confirmed its earnings guidance for full-year 2009 of \$4.45 - \$4.55 per share, which excludes the impact of special items.

"Despite challenging economic and near term business pressures, we continue to deliver solid financial results," said William C. Weldon, Chairman and Chief Executive Officer. "We are continuing to make strategic investments in order to bring important new products to market, positioning us well for long-term growth."

Worldwide Consumer sales of \$3.7 billion for the first quarter represented a decrease of 8.7% versus the prior year with a decline of 1.0% operationally and a negative impact from currency of 7.7%. Domestic sales decreased 5.1%, while international sales decreased 11.6%; which reflected an operational increase of 2.4% and a negative currency impact of 14.0%.

LISTERINE antiseptic mouthrinse and the skin care lines of NEUTROGENA and AVEENO had strong sales performance during the quarter. Also contributing were sales from the recently completed acquisition of DABAO, the leading moisturizer in China. Sales comparisons were negatively impacted due to the initial build of inventory by the trade related to the 2008 launch of ZYRTEC.

Worldwide Pharmaceutical sales of \$5.8 billion for the first quarter represented a decrease versus the prior year of 10.1% with an operational decline of 5.1% and a negative impact from currency of 5.0%. Domestic sales decreased 9.7%, while international sales decreased 10.7%; which reflected an operational increase of 2.8% and a negative currency impact of 13.5%.

CONCERTA, a treatment for attention deficit hyperactivity disorder; REMICADE in the U.S., a biologic approved for the treatment of a number of immune mediated inflammatory diseases; INVEGA and RISPERDAL CONSTA, both antipsychotic medications; and VELCADE, a treatment for multiple myeloma, had strong sales performance during the quarter. Sales results of RISPERDAL, an antipsychotic medication, were negatively impacted by generic competition and sales of PROCRI, a product for the treatment of anemia, were lower due to a decline in the market.

During the quarter, the European Commission approved STELARA for the treatment of moderate to severe plaque psoriasis in adults. Both the European Commission and Health Canada approved a label expansion for PREZISTA, a protease inhibitor, for use in treatment-naïve adults dosed once daily in combination with other antiretroviral agents. In addition, PRILIGY received marketing authorization in several European countries for the on-demand treatment of premature ejaculation in men 18-64 years of age.

The Company also submitted two supplemental new drug applications to the U.S. Food and Drug Administration (FDA) requesting approval for the use of INVEGA tablets for the treatment of schizoaffective disorder as monotherapy and for the treatment of schizoaffective disorder in combination with antidepressants and/or mood stabilizers.

Worldwide Medical Devices and Diagnostics sales of \$5.5 billion for the first quarter represented a decrease of 2.9% versus the prior year with an operational increase of 3.1% and a negative currency impact of 6.0%. Domestic sales increased 2.5%, while international sales decreased 7.4%; which reflected an operational increase of 3.6% and a negative currency impact of 11.0%.

Primary contributors to the operational growth included Ortho-Clinical Diagnostics' professional products; Ethicon's surgical care products; Ethicon Endo-Surgery's minimally invasive products; and DePuy's orthopaedic joint reconstruction, spine, sports medicine and trauma businesses. Also contributing to growth were sales of products acquired as part of the completed acquisition of Mentor Corporation, a leading supplier of medical products for the global aesthetic market. This growth was partially offset by lower sales in the Cordis franchise, reflecting new competitive entries in the drug-eluting stent market as well as the recent divestiture of the Professional Wound Care products.

During the quarter, the Company announced that the FDA granted marketing approval for the NAVISTAR THERMOCOOL Catheter for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation when used with compatible three-dimensional electroanatomic mapping systems. The FDA also approved the THERAKOS CELLEX Photopheresis System for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma that are unresponsive to other forms of treatment.

#### About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

#### NOTE TO INVESTORS

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at [www.investor.jnj.com](http://www.investor.jnj.com). A replay and podcast will be available approximately two hours after the live webcast by visiting [www.investor.jnj.com](http://www.investor.jnj.com).

Copies of the financial schedules accompanying this press release are available at [www.investor.jnj.com/historical-sales.cfm](http://www.investor.jnj.com/historical-sales.cfm). The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company's website at [www.jnj.com](http://www.jnj.com).

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at [www.sec.gov](http://www.sec.gov), [www.jnj.com](http://www.jnj.com) or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

#### Johnson & Johnson and Subsidiaries

#### Supplementary Sales Data

(Unaudited; Dollars in Millions)

#### FIRST QUARTER

	2009	2008	Total	Percent Change	
				Operations	Currency
Sales to customers by segment of business					
Consumer					
U.S.	\$1,726	1,819	(5.1)%	(5.1)	-
International	1,985	2,245	(11.6)	2.4	(14.0)
	3,711	4,064	(8.7)	(1.0)	(7.7)
Pharmaceutical					
U.S.	3,674	4,070	(9.7)	(9.7)	-
International	2,106	2,359	(10.7)	2.8	(13.5)
	5,780	6,429	(10.1)	(5.1)	(5.0)

Med Devices & Diagnostics					
U.S.	2,652	2,588	2.5	2.5	-
International	2,883	3,113	(7.4)	3.6	(11.0)
-----	-----	-----	-----	-----	-----
	5,535	5,701	(2.9)	3.1	(6.0)
-----	-----	-----	-----	-----	-----
U.S.	8,052	8,477	(5.0)	(5.0)	-
International	6,974	7,717	(9.6)	3.0	(12.6)
-----	-----	-----	-----	-----	-----
Worldwide	\$15,026	16,194	(7.2)%	(1.2)	(6.0)
-----	-----	-----	-----	-----	-----

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

FIRST QUARTER

	2009	2008	Total	Percent Change	
				Operations	Currency
-----	-----	-----	-----	-----	-----
Sales to customers by geographic area					
U.S.	\$8,052	8,477	(5.0)%	(5.0)	-
-----	-----	-----	-----	-----	-----
Europe	3,671	4,308	(14.8)	(0.2)	(14.6)
Western Hemisphere excluding U.S.	1,062	1,245	(14.7)	4.5	(19.2)
Asia-Pacific, Africa	2,241	2,164	3.6	8.5	(4.9)
-----	-----	-----	-----	-----	-----
International	6,974	7,717	(9.6)	3.0	(12.6)
-----	-----	-----	-----	-----	-----
Worldwide	\$15,026	16,194	(7.2)%	(1.2)	(6.0)
-----	-----	-----	-----	-----	-----

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

FIRST QUARTER

	2009		2008		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
-----	-----	-----	-----	-----	-----
Sales to customers	\$15,026	100.0	\$16,194	100.0	(7.2)
-----	-----	-----	-----	-----	-----
Cost of products sold	4,251	28.3	4,614	28.5	(7.9)
Selling, marketing					

and administrative expenses	4,608	30.7	5,123	31.6	(10.1)
Research expense	1,518	10.1	1,712	10.6	(11.3)
Interest (income) expense, net	81	0.5	16	0.1	
Other (income) expense, net	(75)	(0.5)	(18)	(0.1)	
-----	---	----	---	----	----
Earnings before provision for taxes on income	4,643	30.9	4,747	29.3	(2.2)
Provision for taxes on income	1,136	7.6	1,149	7.1	(1.1)
-----	-----	---	-----	---	-----
Net earnings	\$3,507	23.3	\$3,598	22.2	(2.5)
-----	-----	----	-----	----	-----
Net earnings per share (Diluted)	\$1.26		\$1.26		
Average shares outstanding (Diluted)	2,789.8		2,866.3		
Effective tax rate	24.5%		24.2%		

REPORTED SALES vs. PRIOR PERIOD (\$MM)

-----  
FIRST QUARTER  
-----

% Change

	2009	2008	Reported	Operational (1)	Currency
	-----	-----	-----	-----	-----
CONSUMER SEGMENT (2)					
-----					
SKIN CARE					
-----					
US	423	382	10.7%	10.7%	-
Intl	419	458	-8.5%	5.4%	-13.9%
WW	842	840	0.2%	7.8%	-7.6%
BABY CARE					
-----					
US	102	115	-11.3%	-11.3%	-
Intl	387	418	-7.4%	4.3%	-11.7%
WW	489	533	-8.3%	0.9%	-9.2%
ORAL CARE					
-----					
US	188	199	-5.5%	-5.5%	-
Intl	177	187	-5.3%	11.6%	-16.9%
WW	365	386	-5.4%	2.8%	-8.2%
OTC/NUTRITIONALS					
-----					
US	726	842	-13.8%	-13.8%	-
Intl	622	752	-17.3%	-2.4%	-14.9%

WW	1,348	1,594	-15.4%	-8.4%	-7.0%
----	-------	-------	--------	-------	-------

WOMEN'S HEALTH

US	149	148	0.7%	0.7%	-
Intl	274	313	-12.5%	0.5%	-13.0%
WW	423	461	-8.2%	0.7%	-8.9%

WOUND CARE / OTHER

US	138	133	3.8%	3.8%	-
Intl	106	117	-9.4%	4.2%	-13.6%
WW	244	250	-2.4%	4.0%	-6.4%

TOTAL CONSUMER

US	1,726	1,819	-5.1%	-5.1%	-
Intl	1,985	2,245	-11.6%	2.4%	-14.0%
WW	3,711	4,064	-8.7%	-1.0%	-7.7%

\* See footnotes below

PHARMACEUTICAL SEGMENT (2)

ACIPHEX/PARIET

US	138	116	19.0%	19.0%	-
Intl	125	161	-22.4%	-8.4%	-14.0%
WW	263	277	-5.1%	3.0%	-8.1%

CONCERTA

US	269	224	20.1%	20.1%	-
Intl	75	66	13.6%	37.0%	-23.4%
WW	344	290	18.6%	23.9%	-5.3%

DURAGESIC/FENTANYL TRANSDERMAL

US	75	75	0.0%	0.0%	-
Intl	156	158	-1.3%	12.6%	-13.9%
WW	231	233	-0.9%	8.5%	-9.4%

LEVAQUIN/FLOXIN

US	408	474	-13.9%	-13.9%	-
Intl	17	22	-22.7%	-3.1%	-19.6%
WW	425	496	-14.3%	-13.4%	-0.9%

PROCRIT/EXPRESX

US	321	334	-3.9%	-3.9%	-
Intl	229	295	-22.4%	-10.0%	-12.4%
WW	550	629	-12.6%	-6.8%	-5.8%

RAZADYNE/REMINYL

US	13	50	-74.0%	-74.0%	-
Intl	88	99	-11.1%	5.1%	-16.2%
WW	101	149	-32.2%	-21.5%	-10.7%

REMICADE

-----

US	737	676	9.0%	9.0%	-
US Exports (4)	286	320	-10.6%	-10.6%	-
Intl	5	2	150.0%	139.3%	10.7%
WW	1,028	998	3.0%	3.0%	-

RISPERDAL/RISPERIDONE

-----

US	118	582	-79.7%	-79.7%	-
Intl	157	227	-30.8%	-24.6%	-6.2%
WW	275	809	-66.0%	-64.2%	-1.8%

RISPERDAL CONSTA

-----

US	126	101	24.8%	24.8%	-
Intl	199	208	-4.3%	13.9%	-18.2%
WW	325	309	5.2%	17.5%	-12.3%

TOPAMAX

-----

US	495	520	-4.8%	-4.8%	-
Intl	107	126	-15.1%	0.1%	-15.2%
WW	602	646	-6.8%	-3.8%	-3.0%

VELCADE

-----

US	-	2	-100.0%	-100.0%	-
Intl	192	182	5.5%	21.8%	-16.3%
WW	192	184	4.3%	20.5%	-16.2%

OTHER

-----

US	688	596	15.4%	15.4%	-
Intl	756	813	-7.0%	9.1%	-16.1%
WW	1,444	1,409	2.5%	11.8%	-9.3%

TOTAL PHARMACEUTICAL

-----

US	3,674	4,070	-9.7%	-9.7%	-
Intl	2,106	2,359	-10.7%	2.8%	-13.5%
WW	5,780	6,429	-10.1%	-5.1%	-5.0%

MAJOR NEW PHARMACEUTICAL PRODUCTS (5)

-----

PREZISTA

-----

US	72	32	125.0%	125.0%	-
Intl	50	42	19.0%	41.1%	-22.1%
WW	122	74	64.9%	77.3%	-12.4%

INVEGA

-----

US	66	57	15.8%	15.8%	-
Intl	25	9	177.8%	221.8%	-44.0%
WW	91	66	37.9%	43.8%	-5.9%

\* See footnotes below

MEDICAL DEVICES AND DIAGNOSTICS (2) (3)

CORDIS (6)

US	246	342	-28.1%	-28.1%	-
Intl	422	459	-8.1%	-1.7%	-6.4%
WW	668	801	-16.6%	-12.9%	-3.7%

DEPUY

US	766	709	8.0%	8.0%	-
Intl	526	578	-9.0%	6.4%	-15.4%
WW	1,292	1,287	0.4%	7.3%	-6.9%

DIABETES CARE

US	270	303	-10.9%	-10.9%	-
Intl	271	312	-13.1%	-1.3%	-11.8%
WW	541	615	-12.0%	-6.0%	-6.0%

ETHICON

US	405	341	18.8%	18.8%	-
Intl	548	604	-9.3%	3.7%	-13.0%
WW	953	945	0.8%	9.1%	-8.3%

ETHICON ENDO-SURGERY

US	454	429	5.8%	5.8%	-
Intl	561	574	-2.3%	11.4%	-13.7%
WW	1,015	1,003	1.2%	8.6%	-7.4%

ORTHO-CLINICAL DIAGNOSTICS

US	277	238	16.4%	16.4%	-
Intl	190	205	-7.3%	3.2%	-10.5%
WW	467	443	5.4%	10.3%	-4.9%

VISION CARE

US	234	226	3.5%	3.5%	-
Intl	365	381	-4.2%	-1.1%	-3.1%
WW	599	607	-1.3%	0.6%	-1.9%

TOTAL MEDICAL DEVICES AND DIAGNOSTICS

US	2,652	2,588	2.5%	2.5%	-
Intl	2,883	3,113	-7.4%	3.6%	-11.0%
WW	5,535	5,701	-2.9%	3.1%	-6.0%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Prior year amounts have been reclassified to conform with current presentation

(4) For external purposes, reported as U.S. sales

(5) Included in Other

(6) Includes sales of Drug-Eluting Stents for Q1 2009 of \$68, \$184 and \$252 million Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q1 2008 of \$169, \$231 and

\$400 million Domestic, International and Worldwide respectively

SOURCE Johnson & Johnson

<http://www.jnj.com>

Copyright (C) 2009 PR Newswire. All rights reserved